BASAGLAR® (insulin glargine) injection 100 units/mL has no dosing differences with Lantus® (insulin glargine injection) 100 units/mL for insulin initiation1,2

Once-daily dose at the same time each day1

Type 2 diabetes1 recommended starting dose

0.2 units/kg once daily or up to 10 units once daily

  • Adjustments to the amount and timing of short- or rapid-acting insulins and dosages of any anti-diabetic medications may be necessary

Type 1 diabetes1 recommended starting dose

~1/3 of the total daily insulin requirements

  • Short- or rapid-acting, premeal insulin should be used to satisfy the remainder of the daily insulin requirements
  • BASAGLAR must be used concomitantly with short-acting insulin

SELECT IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

BASAGLAR is contraindicated during episodes of hypoglycemia, and in patients with hypersensitivity to insulin glargine or any of the excipients in BASAGLAR.

Other dosing information

  • Inject BASAGLAR subcutaneously once a day, any time of day, at the same time every day
  • Individualize and titrate BASAGLAR dosage based on the metabolic needs, blood glucose monitoring results, and glycemic control goal of the individual
  • Dosage adjustments may be needed with changes in physical activity, changes in meal patterns (i.e., macronutrient content or timing of food intake), during acute illness, or changes in renal or hepatic function, and should be made under medical supervision with appropriate glucose monitoring

SELECT IMPORTANT SAFETY INFORMATION

WARNINGS AND PRECAUTIONS

BASAGLAR prefilled pens must never be shared between patients, even if the needle is changed. Sharing poses a risk of transmission of blood borne pathogens.

Titrate BASAGLAR to target fasting plasma glucose (FPG) levels

Increase dose by 1 unit daily until target FPG level is achieved (≤100mg/dL or FPG based on goal of individual patient)3,4

  • Dose titration of BASAGLAR should be individualized according to patient needs and performed under the guidance of a healthcare professional
  • In the event of hypoglycemia, a dose reduction may be necessary

SELECT IMPORTANT SAFETY INFORMATION

WARNINGS AND PRECAUTIONS

Changes in insulin strength, manufacturer, type, injection site, or method of administration may affect glycemic control and predispose to hypoglycemia or hyperglycemia. Any changes in insulin regimen should be made cautiously and only under close medical supervision, and the frequency of blood glucose monitoring should be increased. Due to reports of hypoglycemia and hyperglycemia, advise patients who have repeatedly injected into areas of lipodystrophy or localized cutaneous amyloidosis to change the injection site to unaffected areas and closely monitor blood glucose. For patients with type 2 diabetes, dosage adjustments of concomitant anti-diabetic products may be needed.

Transitioning to BASAGLAR from other insulins1

From Lantus® (insulin glargine injection) 100 units/mL

  • The dose of BASAGLAR should be the same as Lantus
  • The time of day for administration should be determined by the healthcare professional

From Toujeo® (insulin glargine injection) 300 units/mL

  • The recommended initial BASAGLAR dosage is 80% of the Toujeo dose that is being discontinued
  • This dosage reduction will lower the likelihood of hypoglycemia

From NPH (neutral protamine Hagedorn) insulin (twice-daily)

  • The recommended initial BASAGLAR dosage is 80% of the NPH dosage that is being discontinued
  • This dosage reduction will lower the likelihood of hypoglycemia

From intermediate- or long-acting insulin other than Lantus

  • A change in the dose of BASAGLAR may be required and the amount and timing of shorter-acting insulins and doses of any anti-diabetic drugs may need to be adjusted.

SELECT IMPORTANT SAFETY INFORMATION

WARNINGS AND PRECAUTIONS

Hypoglycemia is the most common adverse reaction associated with insulins, including BASAGLAR. Severe hypoglycemia can cause seizures, may be life-threatening, or cause death.

Begin with the BASAGLAR prefilled KwikPen®

  1. Delivers between 1 and 80 units of BASAGLAR in a single injection5
  2. Up-down dial adjustment in 1-unit increments for selecting BASAGLAR dose5
  3. BD Ultra-Fine™ Pen Needles are recommended for use with the BASAGLAR KwikPen.5* The BD Ultra-Fine Nano™ Pen Needle (4 mm x 32 G) has been shown to be effective for all patients†
  4. No refrigeration needed after first injection─store at room temperature up to 86°F (30° C) after first use and dispose after 28 days1,5‡
BASAGLAR (insulin glargine) injection 100 units/mL prefilled KwikPen® with information about product features

BASAGLAR KwikPen must never be shared between patients, even if the needle is changed. Sharing poses a risk of transmission of blood borne pathogens.1

In patients with type 1 diabetes, BASAGLAR must be used concomitantly with short-acting insulin.1

*Multiple sizes may be used.

†In a study, the 4 mm x 32 G Pen Needle provided equivalent glycemic control with reduced pain compared to longer and thicker needles.6

‡Do not freeze or use a KwikPen that has been frozen.

By watching this video with your patients, you can help them learn how to use and store their Basaglar KwikPen. It walks them through steps to prepare, prime, dose, inject, and clean up. This video must be used with the complete Instructions for Use included with the pen.

Support for your patients

References:

  1. BASAGLAR [Prescribing Information]. Indianapolis, IN: Eli Lilly and Company.
  2. Lantus [Prescribing Information]. Bridgewater, NJ: sanofi-aventis U.S. LLC; 2018.
  3. Rosenstock J, Hollander P, Bhargava A, et al. Diabetes Obes Metab. 2015;17:734-741.
  4. Gerstein HC, Yale JF, Harris SB, et al. Diabet Med. 2006;23:736-742.
  5. BASAGLAR KwikPen [Instructions for Use]. Indianapolis, IN: Eli Lilly and Company.
  6. Hirsch LJ, Gibney MA, Qu S, et al. Curr Med Res Opin. 2010;26(6):1531-1541.

INDICATION

BASAGLAR is indicated to improve glycemic control in adults and pediatric patients with type 1 diabetes mellitus and in adults with type 2 diabetes mellitus.

LIMITATION OF USE

BASAGLAR is not recommended for the treatment of diabetic ketoacidosis.

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

BASAGLAR is contraindicated during episodes of hypoglycemia, and in patients with hypersensitivity to insulin glargine or any of the excipients in BASAGLAR.

WARNINGS AND PRECAUTIONS

BASAGLAR prefilled pens must never be shared between patients, even if the needle is changed. Sharing poses a risk of transmission of blood borne pathogens.

Changes in insulin strength, manufacturer, type, injection site, or method of administration may affect glycemic control and predispose to hypoglycemia or hyperglycemia. Any changes in insulin regimen should be made cautiously and only under close medical supervision, and the frequency of blood glucose monitoring should be increased. Due to reports of hypoglycemia and hyperglycemia, advise patients who have repeatedly injected into areas of lipodystrophy or localized cutaneous amyloidosis to change the injection site to unaffected areas and closely monitor blood glucose. For patients with type 2 diabetes, dosage adjustments of concomitant anti-diabetic products may be needed.

Hypoglycemia is the most common adverse reaction associated with insulins, including BASAGLAR. Severe hypoglycemia can cause seizures, may be life-threatening, or cause death.

Accidental mix-ups between insulin products have been reported. To avoid hypoglycemia due to medication errors between BASAGLAR and other insulins, instruct patients to always check the insulin label before each injection.

Severe, life-threatening, generalized allergy, including anaphylaxis, can occur with insulins, including BASAGLAR. If hypersensitivity reactions occur, discontinue BASAGLAR; treat per standard of care and monitor until symptoms and signs resolve. BASAGLAR is contraindicated in patients who have had hypersensitivity reactions to insulin glargine or one of the excipients.

All insulins, including BASAGLAR, cause a shift in potassium from the extracellular to intracellular space, possibly leading to hypokalemia. Untreated hypokalemia may cause respiratory paralysis, ventricular arrhythmia, and death. Monitor potassium levels in patients at risk for hypokalemia if indicated.

Thiazolidinediones (TZDs), which are peroxisome proliferator-activated receptor (PPAR)-gamma agonists, can cause dose-related fluid retention, particularly when used in combination with insulin. Fluid retention may lead to or exacerbate heart failure. These patients should be observed for signs and symptoms of heart failure. If heart failure occurs, dosage reduction or discontinuation of TZD must be considered.

ADVERSE REACTIONS

Adverse reactions commonly (>5%) associated with insulin glargine products are: hypoglycemia, allergic reactions, injection site reaction, lipodystrophy, pruritus, rash, edema, and weight gain.

DRUG INTERACTIONS

Certain drugs may affect glucose metabolism, requiring insulin dose adjustment and close monitoring of blood glucose.

The risk of hypoglycemia may increase when antidiabetic agents, ACE inhibitors, angiotensin II receptor blocking agents, disopyramide, fibrates, fluoxetine, monoamine oxidase inhibitors, pentoxifylline, pramlintide, salicylates, somatostatin analog (e.g., octreotide), and sulfonamide antibiotics are co-administered with BASAGLAR.

The blood glucose lowering effect of BASAGLAR may decrease when co-administered with atypical antipsychotics, corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones. The blood glucose lowering effect of BASAGLAR may increase or decrease when co-administered with alcohol, beta-blockers, clonidine, lithium salts, and pentamidine.

The signs and symptoms of hypoglycemia may be blunted when beta-blockers, clonidine, guanethidine, and reserpine are co-administered with BASAGLAR.

For more information, please see accompanying Full Prescribing Information and Patient Information. Please see Instructions for Use.

BV HCP ISI 27JUL2021